Stock Track | 10x Genomics Soars 6.34% in After-Hours Trading on Strong Q4 Earnings Beat and Positive 2026 Outlook

Stock Track

Feb 13

10x Genomics, Inc. (TXG) saw its stock price surge 6.34% in after-hours trading on Thursday, following the release of its fourth quarter and full year 2025 financial results.

The significant after-hours gain appears driven by the company reporting better-than-expected quarterly performance. 10x Genomics posted a Q4 2025 loss per share of $0.13, which beat the analyst consensus estimate of a $0.20 loss. Quarterly revenue reached $166 million, also exceeding estimates of approximately $159 million. Furthermore, the company's net loss for the quarter narrowed substantially to $16.3 million from $49.0 million in the prior year.

Adding to the positive sentiment, the company provided its revenue outlook for the full year 2026, forecasting between $600 million and $625 million, which aligns with the consensus estimate. Other encouraging details from the report included an improved gross margin of 68% and a strengthened cash position, ending the year with $523.4 million in cash and equivalents.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1162261563"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162261563\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162261563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162261563","market":"nz","top_or_hot":-1,"title":"Stock Track | 10x Genomics Soars 6.34% in After-Hours Trading on Strong Q4 Earnings Beat and Positive 2026 Outlook","media":"Stock Track","content":"<p>10x Genomics, Inc. (TXG) saw its stock price surge 6.34% in after-hours trading on Thursday, following the release of its fourth quarter and full year 2025 financial results.</p><p>The significant after-hours gain appears driven by the company reporting better-than-expected quarterly performance. 10x Genomics posted a Q4 2025 loss per share of $0.13, which beat the analyst consensus estimate of a $0.20 loss. Quarterly revenue reached $166 million, also exceeding estimates of approximately $159 million. Furthermore, the company's net loss for the quarter narrowed substantially to $16.3 million from $49.0 million in the prior year.</p><p>Adding to the positive sentiment, the company provided its revenue outlook for the full year 2026, forecasting between $600 million and $625 million, which aligns with the consensus estimate. Other encouraging details from the report included an improved gross margin of 68% and a strengthened cash position, ending the year with $523.4 million in cash and equivalents.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 10x Genomics Soars 6.34% in After-Hours Trading on Strong Q4 Earnings Beat and Positive 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 10x Genomics Soars 6.34% in After-Hours Trading on Strong Q4 Earnings Beat and Positive 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-13 10:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>10x Genomics, Inc. (TXG) saw its stock price surge 6.34% in after-hours trading on Thursday, following the release of its fourth quarter and full year 2025 financial results.</p><p>The significant after-hours gain appears driven by the company reporting better-than-expected quarterly performance. 10x Genomics posted a Q4 2025 loss per share of $0.13, which beat the analyst consensus estimate of a $0.20 loss. Quarterly revenue reached $166 million, also exceeding estimates of approximately $159 million. Furthermore, the company's net loss for the quarter narrowed substantially to $16.3 million from $49.0 million in the prior year.</p><p>Adding to the positive sentiment, the company provided its revenue outlook for the full year 2026, forecasting between $600 million and $625 million, which aligns with the consensus estimate. Other encouraging details from the report included an improved gross margin of 68% and a strengthened cash position, ending the year with $523.4 million in cash and equivalents.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1162261563","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162261563","pubTimestamp":1770949380,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"10x Genomics, Inc. (TXG) saw its stock price surge 6.34% in after-hours trading on Thursday, following the release of its fourth quarter and full year 2025 financial results.The significant...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"个股追踪|10x Genomics盘后交易飙升6.34%，第四季度盈利强劲，2026年前景乐观","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"10x Genomics, Inc. (TXG) saw its stock price surge 6.34% in after-hours trading on Thursday, following the release of its fourth quarter and full year 2025 financial results.The significant after-hours gain appears driven by the company reporting better-than-expected quarterly performance. 10x Genomics posted a Q4 2025 loss per share of $0.13, which beat the analyst consensus estimate of a $0.20 loss. Quarterly revenue reached $166 million, also exceeding estimates of approximately $159 million. Furthermore, the company's net loss for the quarter narrowed substantially to $16.3 million from $49.0 million in the prior year.Adding to the positive sentiment, the company provided its revenue outlook for the full year 2026, forecasting between $600 million and $625 million, which aligns with the consensus estimate. Other encouraging details from the report included an improved gross margin of 68% and a strengthened cash position, ending the year with $523.4 million in cash and equivalents.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}